Nutritional one-two punch may slow retinitis pigmentosa

Article

A recent analysis of three clinical trials has provided further evidence that a supplement of pure vitamin A combined with an omega-3 rich fatty acid diet can slow vision loss in adults with the common forms of retinitis pigmentosa.

"It does not prevent, cure, or reverse the disease," cautioned Jeff Anshel, OD, FAAO, president of the Ocular Nutrition Society. "It just slows the progression." But with a disease that has no other effective treatments, the positive study data can be seen as a glass half full. "Anything that keeps people with their vision longer is a good thing," he said.

Eliot Berson, MD, and colleagues of Harvard Medical School and the Massachusetts Eye and Ear Infirmary reported that RP patients who take a high dose of vitamin A pal-mitate and consume a diet rich in omega-3 lost an average of 0.59 letters of visual acuity per year. Those taking similar amounts of vitamin A palmitate but consuming lower amounts of omega-3s lost an average of 1.0 letter per year, as measured by Early Treatment or Diabetic Retinopathy Study (EDTRS) distance acuity. The paper was published in the February issue of Archives of Ophthalmology. [Arch Ophthalmol. Published online 13 Feb 2012)

He also noted that the analysis found only vitamin A palmitate, not other forms vitamin A, was effective in postponing vision loss in RP. "Beta-carotene or carrots are not a suitable substitute for vitamin A palmitate in the context of this treatment," Dr. Berson said.

Analyzing data from a total of 357 patients from three clinical trials, each lasting between 4 and 6 years, Dr. Berson and colleagues found that daily doses of 15,000 IU of oral vitamin A palmitate in combination with eating at least 0.2 gram of omega-3 fatty acids daily-the equivalent of one to two 3-ounce servings of oily fish per week-slowed the rate of decline in retinal function.

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.